NCT06929195

Clinical Trial to Evaluate the Tolerance of TQB2210 Injection

Phase I Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB2210 Injection in Subjects With Advanced Malignant Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. The aim of this experiment is to evaluate the tolerability, pharmacokinetics, and preliminary efficacy of TQB2210 injection in patients with advanced malignant tumors, and to assess its effectiveness and phase II recommended dose (RP2D) in advanced malignant tumors with FGFR2b overexpression, such as advanced gastric/gastroesophageal junction cancer.

Conditions

• Advanced Malignant Tumours

Interventions

Type	Name	Description
DRUG	TQB2210 Injection	TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.

Timeline

• Start date: 2025-05-16
• Primary completion: 2026-04-10
• Completion: 2026-04-10
• First posted: 2025-04-16
• Last updated: 2026-04-14

Locations

7 sites across 1 country: China